Trust Signals
Reviewed by the FormBlends Medical Team. Sources: PubMed, FDA drug databases, peer-reviewed trial publications. All claims rated by evidence tier. No affiliate relationship with any peptide vendor. Last updated 2026-05-29.Key Takeaways
- Tirzepatide produced a mean 21 percent body weight reduction at 15 mg in the SURMOUNT-1 trial (n=2,539), the largest effect size of any approved or investigational peptide for obesity to date.
- Semaglutide's 7-day half-life comes from a C18 fatty di-acid linker at amino acid position 26, not from the peptide backbone itself. Without that modification, native GLP-1 is cleared in roughly 2 minutes.
- AOD-9604's early phase-2 weight-loss signals were not replicated in later trials; its developer discontinued the obesity program, and it holds no approved indication anywhere in the world.
- Oral bioavailability for most unprotected research peptides is well under 1 percent. Claims for oral fat-loss peptides require extraordinary evidence to be credible.
- Weight regain after stopping semaglutide averages roughly two-thirds of lost weight within one year (STEP 4 withdrawal data), confirming these are maintenance therapies, not cures.
What's the Best Peptide for Weight Loss? (Direct Answer)
Tirzepatide and semaglutide are the best-evidenced peptides for weight loss by a wide margin. Both are FDA-approved, have phase-3 RCT data in thousands of patients, and produce clinically meaningful fat loss. Every other peptide discussed in wellness communities sits several evidence tiers below them.Table of Contents
- Evidence Ledger: All Major Peptides Ranked
- How Do Weight-Loss Peptides Actually Work? (With Numbers)
- The Short List: Tirzepatide, Semaglutide, and the Gap Below
- Research Peptides: CJC-1295, Ipamorelin, AOD-9604
- What Most Pages Get Wrong About Peptides and Fat Loss
- The Chemistry Behind the Rules: Why Peptides Degrade and Why Oral Dosing Rarely Works
- Honest Head-to-Head: Peptides vs. Their Real Alternatives
- Label and COA Literacy: How to Judge What You Are Buying
- FAQ
- Sources
- Disclaimers
Evidence Ledger: All Major Peptides Ranked
Each row below reflects the strongest evidence that currently exists for weight or fat loss specifically. Evidence for other indications (e.g., glycemic control) is not counted.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Peptide | Best Evidence Type | Effect Direction | Sample Size (best trial) | Confidence (Weight Loss) |
|---|---|---|---|---|
| Tirzepatide | Human phase-3 RCT (SURMOUNT-1) | Strong fat loss (~21% body weight) | n=2,539 | High |
| Semaglutide 2.4 mg | Human phase-3 RCT (STEP 1) | Strong fat loss (~15% body weight) | n=1,961 | High |
| Liraglutide 3.0 mg | Human phase-3 RCT (SCALE) | Moderate fat loss (~8% body weight) | n=3,731 | High |
| AOD-9604 | Phase-2 human trial (single publication); effect not replicated | Small, not replicated | Approximately a few hundred participants across phase-2 work | Very Low |
| CJC-1295 / Ipamorelin | Animal + mechanism only for fat loss | Indirect (GH/IGF-1 elevation) | No fat-loss RCT | Very Low |
| BPC-157 | Animal (GI/angiogenesis models) | No meaningful weight-loss signal | No human trial | Very Low |
| Tesamorelin | Human RCT (HIV-associated lipodystrophy) | Visceral fat reduction in specific population | n=412 (Falutz et al.) | Moderate (narrow indication) |
| MOTS-c | Animal + small human pilot | Metabolic improvement, not weight loss primary | n=less than 50 | Very Low |
How Do Weight-Loss Peptides Actually Work? (With Numbers)
GLP-1 receptor agonism (semaglutide, liraglutide). GLP-1 receptors are expressed in hypothalamic arcuate and paraventricular nuclei. Agonism reduces food intake by slowing gastric emptying and signaling satiety via vagal afferents. In pharmacokinetic terms, native GLP-1 has a plasma half-life of roughly 1 to 2 minutes due to DPP-4 cleavage at the alanine at position 2. Semaglutide substitutes alanine with aminoisobutyric acid at position 8 to resist DPP-4, and attaches a C18 fatty di-acid chain at position 26 via a linker, enabling albumin binding that extends its half-life to roughly 165 hours (about 7 days). That pharmacokinetic engineering, not a new target, is what makes once-weekly dosing possible.
Dual GIP/GLP-1 agonism (tirzepatide). Tirzepatide is a single 39-amino-acid peptide that activates both GLP-1 and GIP receptors. GIP receptor co-agonism appears to enhance the GLP-1 satiety effect while reducing nausea, allowing dose escalation to 15 mg weekly. The incremental weight loss over semaglutide is likely driven by additive receptor signaling in hypothalamus and adipose tissue, though the exact contribution of each receptor pathway continues to be studied.
Growth hormone secretagogue route (CJC-1295, Ipamorelin). CJC-1295 is a GHRH analogue; Ipamorelin is a ghrelin receptor agonist. Both raise GH pulse amplitude and secondarily raise IGF-1. Elevated GH promotes lipolysis in adipocytes via hormone-sensitive lipase activation and reduces glucose uptake in peripheral tissue. However, this mechanism does NOT prove a net fat-loss effect in eumetabolic adults on ad libitum diets. The GH axis is tightly regulated; supraphysiological pulsatile GH does not automatically translate to sustained fat loss without caloric restriction.
The Short List: Tirzepatide, Semaglutide, and the Gap Below
Tirzepatide (Zepbound for obesity, Mounjaro for T2D). SURMOUNT-1 enrolled 2,539 adults with a BMI of 30 or higher. At 72 weeks, the 15 mg group reached a mean weight reduction of roughly 21 percent. Gastrointestinal side effects (nausea, vomiting, diarrhea) affected a significant minority during dose escalation and were the primary reason for discontinuation in about 4 to 5 percent of participants. It requires a prescription in all markets.
Semaglutide 2.4 mg weekly (Wegovy). STEP 1 (Wilding et al., NEJM 2021, n=1,961) remains the definitive citation. Mean weight loss was 14.9 percent vs. 2.4 percent for placebo at 68 weeks. The STEP 4 withdrawal trial (Rubino et al., JAMA 2021) showed that stopping semaglutide after 20 weeks of treatment led to regain of about two-thirds of lost weight by week 120. This is the most important single fact about GLP-1 therapy that most weight-loss content omits.
The gap. No other peptide discussed in wellness or research communities comes close to the effect sizes or evidence quality of these two. Liraglutide 3.0 mg (Saxenda) is a legitimate third option with phase-3 data, but produces roughly half the weight loss of semaglutide and requires daily injection.
Research Peptides: CJC-1295, Ipamorelin, AOD-9604
AOD-9604 is hGH fragment 177-191 (the C-terminal 15 residues). Early phase-2 clinical work in obese adults, conducted as part of the METASCREEN development program by Monash University and Aeterna Zentaris, explored oral dosing and found modest signals compared to placebo in at least one trial. The effect was small and a subsequent phase-2b program did not replicate a meaningful benefit. Aeterna Zentaris discontinued the obesity program. AOD-9604 received Generally Recognized as Safe (GRAS) status from an independent panel for use as a food ingredient in the US, but GRAS status covers a specific intended use and does not constitute evidence of fat-loss efficacy. The precise sample sizes, dosing arms, and statistical outcomes of the METASCREEN trials are best verified directly through the published primary literature and Aeterna Zentaris regulatory filings rather than secondary summaries.
CJC-1295 was originally developed by ConjuChem as a GHRH analogue with extended half-life via drug affinity complex (DAC) technology. A small human PK/PD study (Teichman et al., Journal of Clinical Endocrinology and Metabolism, 2006) confirmed dose-dependent GH and IGF-1 elevation with a half-life of roughly 6 to 8 days. That study was not designed or powered to measure body composition or weight as an endpoint. No subsequent body composition RCT has been completed and published.
Ipamorelin is a pentapeptide (Ala-His-D-2Nal-D-Phe-Lys-NH2) that selectively activates the GHSR-1a receptor with minimal cortisol or prolactin stimulation compared to older secretagogues. Its main studied application has been GI motility (postoperative ileus), not fat loss. Human fat-loss data does not exist in peer-reviewed form.
What Most Pages Get Wrong About Peptides and Fat Loss
Conflating "affects metabolism" with "causes fat loss." Almost every peptide affects some metabolic pathway. That is not evidence of clinically significant weight reduction. Most listicles cite GH-secretagogue mechanisms as if they were equivalent to GLP-1 trial data. They are not.
Ignoring the sourcing reality. Research peptides sold as "not for human consumption" are not manufactured under FDA cGMP standards. Independent analytical testing of commercially available research peptides has repeatedly found purity and content discrepancies, though the scale of the problem varies by supplier and time period. Bacterial endotoxin contamination is a practical risk in any non-sterile injectable. This distinction is rarely mentioned in wellness content.
The compounded semaglutide salt issue. During the semaglutide shortage period, some compounding pharmacies produced semaglutide acetate or sodium salts rather than the approved semaglutide base. The FDA issued statements in 2024 noting that these salts have not been shown to be bioequivalent to the approved drug. The potency difference between semaglutide base and its salt forms is not trivial and is not addressed in most consumer-facing content.
Omitting the weight-regain data. Any page that tells you a peptide "causes weight loss" without telling you what happens when you stop is giving you half the picture. For GLP-1 agonists, the STEP 4 trial makes clear this is a chronic therapy for most patients.
The Chemistry Behind the Rules: Why Peptides Degrade and Why Oral Dosing Rarely Works
Why inject instead of swallowing. Peptide bonds are hydrolyzed by serine proteases (trypsin, chymotrypsin) and metalloproteases in the small intestine. The brush border of the duodenum expresses aminopeptidases and dipeptidyl peptidases that cleave from the N-terminus. Even if a peptide survives luminal digestion, tight junctions in the intestinal epithelium block paracellular transport for molecules above roughly 1,000 Da. Most bioactive peptides of interest for weight loss are between 1,000 and 5,000 Da. The result is that oral bioavailability without specialized formulation is well under 1 percent for most candidates.
Why oral semaglutide works (barely, and expensively). Oral semaglutide (Rybelsus) co-formulates the peptide with 300 mg of sodium N-(8-(2-hydroxybenzoyl)aminocaprylate), known as SNAC. SNAC transiently increases local gastric pH and transcellular absorption at the gastric epithelium before proteases in the small intestine can act. Even so, absolute bioavailability of oral semaglutide is roughly 1 percent, and it must be taken fasting with no more than 120 mL of water, waited on for 30 minutes before any food. The dose for glycemic control (7 to 14 mg oral) is substantially higher than equivalent subcutaneous doses precisely because of this bioavailability ceiling.
Why peptides must be stored cold. Asparagine residues in peptide chains undergo deamidation at room temperature, converting to aspartate or isoaspartate. This alters the peptide's charge, secondary structure, and receptor-binding geometry. The rate of deamidation accelerates with temperature and depends on adjacent amino acid sequence. Refrigeration (2 to 8 degrees Celsius) slows but does not stop this reaction. Reconstituted peptides in bacteriostatic water are not stable at room temperature for more than a few days. This is not a vendor-invented rule. It is basic peptide chemistry.
Honest Head-to-Head: Peptides vs. Their Real Alternatives
| Agent | Class | Mean Weight Loss (Best Trial) | Approval Status | Where the Peptide Wins | Where the Peptide Loses |
|---|---|---|---|---|---|
| Tirzepatide | GIP/GLP-1 peptide | ~21% (SURMOUNT-1) | FDA-approved (obesity) | Largest effect size, once weekly | Cost, GI side effects, not curative |
| Semaglutide 2.4 mg | GLP-1 peptide | ~15% (STEP 1) | FDA-approved (obesity) | Robust CV outcome data (SELECT trial) | Inferior to tirzepatide on weight alone |
| Phentermine/topiramate ER | Small molecule combination | ~10% (CONQUER trial) | FDA-approved | Lower cost, oral | Cardiovascular and teratogenicity concerns |
| Naltrexone/bupropion | Small molecule combination | ~5-6% (COR-II trial) | FDA-approved | Oral, addresses craving | Much smaller effect, neuropsychiatric warnings |
| CJC-1295/Ipamorelin | Research peptide stack | Not established | Not approved | Possible body composition shift (speculative) | No fat-loss RCT, purity risk, no legal medical use |
| AOD-9604 | Research peptide (hGH fragment) | Small, unreplicated | Not approved | Possibly fewer IGF-1 driven side effects than full GH | Phase-2b failure, no reliable supply chain |
Label and COA Literacy: How to Judge What You Are Buying
For research peptides, a COA is the minimum bar, not a gold standard. A certificate of analysis should include: HPLC purity (look for 98 percent or higher), mass spectrometry confirming the correct molecular weight matches the peptide sequence, and an endotoxin test using the limulus amebocyte lysate (LAL) assay with a result below 1 EU per mg. If the COA comes from the same company selling the product, treat it with appropriate skepticism. Third-party lab letterhead with a traceable lab name and accreditation number is the minimum independent confirmation.
For compounded GLP-1 products: Ask the pharmacy for their 503A or 503B registration, confirm the base form (semaglutide base vs. salt), and request the lot-level COA from the API supplier. The FDA's drug shortage database can tell you whether a shortage exemption that legally permits compounding is still active.
Reconstitution math. A common research peptide vial contains 5 mg (5,000 mcg) lyophilized. If you add 2.5 mL bacteriostatic water, the concentration is 2 mg/mL (2,000 mcg/mL). A 0.1 mL (10-unit insulin syringe) draw delivers 200 mcg. This arithmetic prevents dosing errors that are common when people conflate volume with dose. Write the concentration on the vial after reconstitution.
What degraded peptide looks like. Lyophilized peptide should be a white to off-white powder or cake. After reconstitution, the solution should be clear to very slightly opalescent and colorless. Yellow or brown color indicates oxidation (methionine or tryptophan residues most often). Visible particles suggest aggregation or contamination. Do not use a visually abnormal preparation.
FAQ
What's the best peptide for weight loss overall?
Semaglutide (Ozempic/Wegovy) has the strongest human clinical evidence, producing roughly 15 percent mean body weight reduction in the STEP 1 trial. Tirzepatide (Mounjaro/Zepbound) now surpasses it in head-to-head data. Research-only peptides like AOD-9604 and CJC-1295 have far weaker evidence and no approved indication.
Is semaglutide really a peptide?
Yes. Semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide, modified with a C18 fatty di-acid linker at position 26 to extend its half-life to roughly 7 days. That modification is what separates it from native GLP-1, which has a half-life of about 2 minutes.
What does CJC-1295 actually do for weight loss?
CJC-1295 is a GHRH analogue that raises growth hormone pulse amplitude and IGF-1 levels. Elevated GH can shift substrate utilization toward fat oxidation, but no human RCT has measured body composition as a primary endpoint for CJC-1295 alone used for weight loss.
Does AOD-9604 work for fat loss in humans?
AOD-9604 is a fragment of human growth hormone (residues 177-191). Early phase-2 trials in obese humans showed modest weight loss signals vs. placebo, but subsequent trials did not replicate a meaningful effect and the developer discontinued the obesity program. No regulatory body has approved it.
Can peptides replace diet and exercise for weight loss?
No. Even in semaglutide trials, participants followed a reduced-calorie diet and exercise counseling. Weight regain after stopping semaglutide (about two-thirds of lost weight within one year in the STEP 4 withdrawal study) confirms that lifestyle remains the foundation.
What is tirzepatide and how does it compare to semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURMOUNT-1 trial found a mean body weight reduction of roughly 21 percent at the 15 mg dose over 72 weeks, compared to roughly 15 percent for semaglutide 2.4 mg in STEP 1. It currently has superior weight loss data.
Are research peptides like Ipamorelin safe for weight loss?
Ipamorelin is a ghrelin receptor agonist studied for GI motility and GH release. Human safety data for weight loss use is minimal, supply chain purity is uncontrolled, and bacterial endotoxin contamination is a real risk. It is not approved for any indication in humans.
Why do some compound pharmacies offer peptides for weight loss?
During semaglutide shortages, some 503A and 503B compounding pharmacies legally compounded semaglutide salts rather than the approved base. The FDA has raised concerns about the safety equivalence of these salts versus the approved drug. As of early 2025, shortage exemptions have narrowed significantly.
How do I read a COA for a research peptide?
Look for HPLC purity above 98 percent, mass spectrometry confirmation of the correct molecular weight, and an endotoxin value below 1 EU per mg (LAL assay). A COA from the same vendor selling the product is a conflict of interest; third-party lab letterhead is the minimum standard.
What happens to peptides in the digestive system?
Most unmodified peptides are cleaved by peptidases in the GI lumen and brush border before absorption. Oral bioavailability for most unprotected peptides is well under 1 percent. That is why GLP-1 agonists are injectable or use specialized oral formulations (oral semaglutide uses an absorption enhancer, SNAC, at 300 mg per tablet).
Does BPC-157 cause weight loss?
There is no credible human evidence that BPC-157 causes meaningful weight loss. Its proposed mechanisms involve angiogenesis and GI mucosal repair. Animal studies show some metabolic effects but are not translatable to a weight-loss claim for humans at this time.
What is the biggest mistake people make when buying peptides for weight loss?
Conflating research-grade peptides with pharmaceutical-grade drugs. Research peptides are not manufactured under cGMP, are not sterility-tested to USP standards, and are frequently mislabeled for content. Substituting a research peptide for a prescribed GLP-1 agonist is both medically and legally different.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. (STEP 1 trial)
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414-1425. (STEP 4 withdrawal trial)
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1 trial)
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. (Note: this is a preclinical mouse study; human phase-2 METASCREEN program results should be verified in primary regulatory filings and any published clinical reports separately.)
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. (Tesamorelin/EGRIFTA)
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015;373(1):11-22. (SCALE trial)
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019;10:155. (GLP-1 modification chemistry)
- Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740-756.
- US FDA. Drug Shortages: Semaglutide. FDA Drug Shortage Database. Accessed 2026.
- US FDA. Compounding and the FDA: Questions and Answers. FDA.gov. Updated 2024.